Amendments to the Specification

Please replace the Cross-Reference to Related Applications paragraph at page 1, lines 7 through 12 with the following amended paragraph:

The present application is a continuation-in-part of ~~prior-filed~~ application U.S. Patent Application ~~Serial~~ No. 08/842,898, entitled "Novel CRSP-1 Compositions and Therapeutic and Diagnostic Uses Therefor", filed April 17, 1997 (now abandoned), which is a continuation-in-part of U.S. Patent Application ~~Serial~~ No. 08/843,704, filed April 16, 1997 (now abandoned)[[.]] ~~The present application also~~ and claims the benefit of ~~prior-filed provisional application~~ U.S. Patent Application No. 60/071,589, filed January 15, 1998 ~~(Attorney Docket No. MEI-008-1)~~. The contents of each of the above-referenced patent applications are incorporated herein by this reference in their entirety.

Docket No.: MNI-108KCE

Group Art Unit: 1636

In the specification:

Replace the title of the specification at page 1, line 1 with the following title:

NOVEL CRSP-2 PROTEIN MOLECULES AND [NUCLEIC ACID MOLECULES AND] USES THEREFOR

Replace the paragraph at page 3, line 31 through page 4, line 6 of the specification with the following paragraph,

Another embodiment of the invention features CRSP nucleic acid molecules which specifically detect CRSP nucleic acid molecules relative to nucleic acid molecules encoding non-CRSP proteins. For example, in one embodiment, a CRSP nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotides 470-2479 of nucleotide sequence shown in SEQ ID NO:1, to nucleotides 1-475 of nucleotide sequence shown in SEQ ID NO:4, or to nucleotides 1-600 of nucleotide sequence shown in SEQ ID NO:7, or hybridizes under stringent conditions to the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633 [_____], or to the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633 [_____]. In another embodiment, the CRSP nucleic acid molecule is at least 500 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10 or a complement thereof.

Replace the section beginning from page 14, line 3 through page 21, line 7 of the specification with the following section,

A nucleic acid molecule of the present invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633 [_____], the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633 [_____], or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or portion of the nucleic acid sequence of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633 [_____], or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633 [_____] as a hybridization probe, CRSP nucleic acid molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, J., Fritsh, E F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual 2nd. ed., Cold Spring Harbor Laboratory.* Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

Moreover, a nucleic acid molecule encompassing all or a portion of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, or SEQ ID NO:10, or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98633 [_____], or the nucleotide sequence